Moderna
Moderna is a biotechnology company specializing in messenger RNA (mRNA) vaccine and immunotherapy development. The company gained prominence following its COVID-19 vaccine and continues to expand its mRNA platform across multiple therapeutic areas. In recent regulatory progress, Moderna's experimental mRNA-based influenza vaccine secured unanimous support from an FDA advisory panel, with the agency identifying no major safety concerns in its evaluation. This advancement reflects the company's ongoing effort to extend its mRNA technology platform beyond COVID-19 to address other infectious diseases.
Latest on Moderna
pharma
Moderna and Merck's Personalized Cancer Vaccine Clears Its First Phase 3 Test
stocks
Wall Street Roars Back as Reports of a U.S.-Iran Peace Deal Lift Stocks
pharma
FDA Advisory Panel Unanimously Backs Moderna's Flu Vaccine
pharma